FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205961736> ?p ?o ?g. }

• W3205961736 endingPage "A1237" @default.
• W3205961736 startingPage "A1237" @default.
• W3205961736 abstract "TOPIC: Diffuse Lung Disease TYPE: Original Investigations PURPOSE: Evaluate the impact of an idiopathic pulmonary fibrosis (IPF) clinical pharmacist and specialty pharmacy services on patient outcomes. METHODS: This is a retrospective chart review evaluating patients prescribed anti-fibrotic treatment with nintedanib (Ofev®) or pirfenidone (Esbriet®) at an interstitial lung disease (ILD) specialty clinic from the period of 9/2016-1/2021. Clinical outcomes evaluated include time to treatment discontinuation, adverse event management, and markers of IPF progression. Non-clinical outcomes including assessment for appropriate adherence as indicated by proportion of days covered (PDC) of ≥80%, time to anti-fibrotic treatment initiation following pharmacy receipt of prescription (turnaround time), patient financial obligation, and financial assistance provided will also be evaluated. Data will be summarized using descriptive statistics and compared to available data from anti-fibrotic clinical trials, internal data, and other relevant literature. RESULTS: Chart review for this research is in process as of current. Preliminary results suggest that most patients managed by the IPF pharmacist and specialty pharmacy (n = 31) with 3 or more anti-fibrotic prescription fills maintained appropriate adherence as evidenced by a PDC ≥80% in 83% (n = 26) of patients. Patients with a PDC of <80% (n = 5) were reviewed for clinically appropriate reasons for exclusion with 60% (n = 3) ultimately being excluded from PDC calculation for having a clinically appropriate reason for non-adherence. The average prescription turnaround time was 1.94 days (range 1-13 days). Data will be reviewed to obtain additional outcomes as indicated in the methods section and is expected to be completed ~6/2021. CONCLUSIONS: Though this chart review is still in process, preliminary results from anti-fibrotic dispensing data indicate that the majority (92.8%) of patients achieved appropriate adherence to medication therapy with a PDC of ≥80% following exclusion for clinically appropriate reasons for non-adherence such as medication adjustment for toxicity. Additionally, results showed that patients who receive anti-fibrotic prescriptions through the internal specialty pharmacy generally received their medications in 2 days or less, indicating only minimal delays in treatment initiation. Though data review is not final as of current, preliminary review suggests that patients who were not managed by the internal specialty pharmacy and IPF pharmacist were more likely to have a PDC of <80%, indicating potential issues with adherence in this population. Further data review will elucidate the benefits of including an IPF-focused clinical pharmacist and integrated specialty pharmacy in the multi-disciplinary management of IPF patients. CLINICAL IMPLICATIONS: Results will be used to aid in elaborating on the role of an IPF-focused clinical pharmacist in the multi-disciplinary management of IPF patients, lead to further generalized research into the impacts of a pharmacist within an ILD/Pulmonary clinic, and will highlight the importance of collaboration between an IPF-focused clinical pharmacist and an integrated health-system specialty pharmacy. DISCLOSURES: No relevant relationships by Charles Bodreau, source=Web Response No relevant relationships by Said Chaaban, source=Web Response No relevant relationships by Stephen Hobbs, source=Web Response No relevant relationships by Thom Platt, source=Web Response" @default.
• W3205961736 created "2021-10-25" @default.
• W3205961736 creator A5060341606 @default.
• W3205961736 creator A5070351668 @default.
• W3205961736 creator A5076074035 @default.
• W3205961736 creator A5089421686 @default.
• W3205961736 date "2021-10-01" @default.
• W3205961736 modified "2023-09-25" @default.
• W3205961736 title "IMPACT OF A CLINICAL PHARMACIST AND SPECIALTY PHARMACY SERVICES ON TREATMENT OUTCOMES IN AN IDIOPATHIC PULMONARY FIBROSIS SPECIALITY CLINIC" @default.
• W3205961736 doi "https://doi.org/10.1016/j.chest.2021.07.1137" @default.
• W3205961736 hasPublicationYear "2021" @default.
• W3205961736 type Work @default.
• W3205961736 sameAs 3205961736 @default.
• W3205961736 citedByCount "1" @default.
• W3205961736 countsByYear W32059617362023 @default.
• W3205961736 crossrefType "journal-article" @default.
• W3205961736 hasAuthorship W3205961736A5060341606 @default.
• W3205961736 hasAuthorship W3205961736A5070351668 @default.
• W3205961736 hasAuthorship W3205961736A5076074035 @default.
• W3205961736 hasAuthorship W3205961736A5089421686 @default.
• W3205961736 hasBestOaLocation W32059617361 @default.
• W3205961736 hasConcept C10446079 @default.
• W3205961736 hasConcept C104863432 @default.
• W3205961736 hasConcept C126322002 @default.
• W3205961736 hasConcept C159110408 @default.
• W3205961736 hasConcept C177713679 @default.
• W3205961736 hasConcept C1862650 @default.
• W3205961736 hasConcept C194828623 @default.
• W3205961736 hasConcept C20387591 @default.
• W3205961736 hasConcept C2426938 @default.
• W3205961736 hasConcept C2777714996 @default.
• W3205961736 hasConcept C2778341716 @default.
• W3205961736 hasConcept C2778715236 @default.
• W3205961736 hasConcept C2779457091 @default.
• W3205961736 hasConcept C2779832356 @default.
• W3205961736 hasConcept C2780171596 @default.
• W3205961736 hasConcept C512399662 @default.
• W3205961736 hasConcept C71924100 @default.
• W3205961736 hasConceptScore W3205961736C10446079 @default.
• W3205961736 hasConceptScore W3205961736C104863432 @default.
• W3205961736 hasConceptScore W3205961736C126322002 @default.
• W3205961736 hasConceptScore W3205961736C159110408 @default.
• W3205961736 hasConceptScore W3205961736C177713679 @default.
• W3205961736 hasConceptScore W3205961736C1862650 @default.
• W3205961736 hasConceptScore W3205961736C194828623 @default.
• W3205961736 hasConceptScore W3205961736C20387591 @default.
• W3205961736 hasConceptScore W3205961736C2426938 @default.
• W3205961736 hasConceptScore W3205961736C2777714996 @default.
• W3205961736 hasConceptScore W3205961736C2778341716 @default.
• W3205961736 hasConceptScore W3205961736C2778715236 @default.
• W3205961736 hasConceptScore W3205961736C2779457091 @default.
• W3205961736 hasConceptScore W3205961736C2779832356 @default.
• W3205961736 hasConceptScore W3205961736C2780171596 @default.
• W3205961736 hasConceptScore W3205961736C512399662 @default.
• W3205961736 hasConceptScore W3205961736C71924100 @default.
• W3205961736 hasIssue "4" @default.
• W3205961736 hasLocation W32059617361 @default.
• W3205961736 hasOpenAccess W3205961736 @default.
• W3205961736 hasPrimaryLocation W32059617361 @default.
• W3205961736 hasRelatedWork W2195044858 @default.
• W3205961736 hasRelatedWork W2303933533 @default.
• W3205961736 hasRelatedWork W2333432793 @default.
• W3205961736 hasRelatedWork W2729310628 @default.
• W3205961736 hasRelatedWork W2768138587 @default.
• W3205961736 hasRelatedWork W2905736666 @default.
• W3205961736 hasRelatedWork W2981640996 @default.
• W3205961736 hasRelatedWork W3022464006 @default.
• W3205961736 hasRelatedWork W4205609963 @default.
• W3205961736 hasRelatedWork W4311236132 @default.
• W3205961736 hasVolume "160" @default.
• W3205961736 isParatext "false" @default.
• W3205961736 isRetracted "false" @default.
• W3205961736 magId "3205961736" @default.
• W3205961736 workType "article" @default.